Heart Centre Rigshospitalet Enhances Leadership in Patient Care with Adoption of Latest Robotic Technology
06 Settembre 2023 - 2:56PM
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical
robotics for minimally invasive endovascular intervention, today
announced that physicians at Heart Centre Rigshospitalet of
Copenhagen University Hospital successfully treated the first
patients using Stereotaxis’ Genesis Robotic Magnetic Navigation
System. The Genesis system is the latest and most advanced robotic
technology available for the treatment of heart rhythm disorders.
Rigshospitalet is among the first in Europe, and the only hospital
in Denmark, to offer the Genesis system to patients.
Electrophysiologists at The Heart Centre
Rigshospitalet were early pioneers, and are global leaders, in the
use of advanced robot technology for the treatment of cardiac
arrhythmias. Since installation of the first robotic system in
2006, Rigshospitalet physicians have successfully treated over
5,000 patients using Stereotaxis’ robotic technology. The hospital
remains among the only hospitals in Denmark permitted to treat
complex congenital and pediatric arrhythmias and has used robotic
technology to treat patients where traditional approaches would be
unsuccessful.
“Robotics is an essential part of our
electrophysiology program at Rigshospitalet and reflects our
continued commitment to advanced technology and techniques that
improve patient care,” said Dr. Peter Karl Jacobsen, Head of
Invasive Electrophysiology at Rigshospitalet. “I am very impressed
with the speed and precision of the Genesis system and look forward
to the positive impact it will have when treating our patients with
complex heart rhythm disorders.”
“We are excited to bring the most advanced
technology to Denmark,” added Dr. Xu Chen, Chief Physician and
Clinical Cardiac Electrophysiologist “We have built a leading
robotic program and are excited to continue to provide safe and
effective therapy to patients unsuitable for traditional
treatments.”
Robotic Magnetic Navigation introduces the
benefits of robotic precision and safety to cardiac ablation, a
common minimally invasive procedure to treat arrhythmias. Tens of
millions of individuals worldwide suffer from arrhythmias—abnormal
heart rhythms that result when the heart beats too quickly, too
slowly, or with an irregular pattern. When left untreated,
arrhythmias may significantly increase the risk of stroke, heart
failure, and sudden cardiac arrest.
“We are delighted to extend our partnership with
the team at Rigshospitalet,” said David Fischel, Chairman and CEO
of Stereotaxis. “We look forward to continuing a strong
collaboration that advances patient care, clinical science, and
technology development in electrophysiology.”
About StereotaxisStereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical
robotics for minimally invasive endovascular intervention. Its
mission is the discovery, development and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100Investors@Stereotaxis.com
Grafico Azioni Stereotaxis (AMEX:STXS)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Stereotaxis (AMEX:STXS)
Storico
Da Set 2023 a Set 2024